Can-Fite BioPharma
AboutSciencePipelineInvestor InformationContact Us

Investor Information

Investor Information

Share Information
Analyst Coverage
Press Releases
US Filings
Events
Financial Statements
Presentation
Code of Conduct
Shareholders Meetings

Press Releases

2013

  November 15, 2013
Can-Fite BioPharma Announces Approval of ADR Listing on NYSE MKT
            Hebrew version

          English version
  October 24, 2013
Can-Fite BioPharma Successfully Concludes $6,000,000 Public Offering
            Hebrew version

          English version
  October 23, 2013
Can-Fite Public Offering to Raise Money for its Up List
            Hebrew version

          English version
  October 22, 2013
Can-Fite BioPharma Announces Clinical and Corporate Developments for Near-Term Events
            Hebrew version

          English version
  October 3, 2013
Can-Fite’s Subsidiary OphthaliX to Present at Ophthalmology Futures European Forum
          Hebrew version

          English version
  September 12, 2013
Can-Fite’s Level II ADRs Commence Trading on the U.S. OTC Markets
            Hebrew version

          English version
  September 8, 2013
OphthaliX: European Patent Office Grants a Patent for the Treatment of Sjogren`s Syndrome
          Hebrew version

          English version
  August 27, 2013
Can-Fite to Initiate a Phase II Study with CF102 in 130 Patients with Advanced Liver Cancer
          Hebrew version

          English version
  August 12, 2013
Can-Fite BioPharma Announces the Completion of Patient Enrollment for the Phase 2b Rheumatoid Arthritis Study
          Hebrew version

          English version
  July 17, 2013
OphthaliX to Initiate a Phase II study of CF101 for the Treatment of Uveitis
          Hebrew version

          English version
  July 2, 2013
Can-Fite BioPharma was Granted a US Patent for its 3rd drug candidate CF602 earmarked for the Treatment of Sexual Dysfunction
          Hebrew version

          English version
  May 12, 2013
OphthaliX: Third Party Presented New Data at the ARVO 2013 Annual Meeting in Seattle, WA, Validating the use of A3 Adenosine Receptor Agonists for Lowering Intra Ocular Pressure and for the Treatment of Glaucoma
          Hebrew version

          English version
  March 17, 2013
OphthaliX Inc. Announces the Completion of Patient Enrollment for the Phase 3 Dry Eye Syndrome Study
          Hebrew version

          English version
  February 5, 2013
Can-Fite Announces Successful Completion of a Public Offering
          Hebrew version

          English version
  February 4, 2013
Shelf Prospectus Report
           Hebrew version

           English version
  January 29, 2013
Can-Fite Announces 2013 Milestones and Corporate Strategy
          Hebrew version

          English version
  January 21, 2013
Can-Fite Drugs’ API to be Manufactured in China
          Hebrew version

          English version
  January 16, 2013
Can Fite is preparing for a phase II of CF102 for the treatment of primary liver cancer: the optimal dose of CF102 has been determined
          Hebrew version

          English version 

 

2012

  December 30, 2012
Positive Quantitative Interim Analysis Data of the CF101 Psoriasis Phase 2/3 Study

          Hebrew version

          English version

  December 13, 2012
Dr. Gil Ben-Menachem appointed Chief Executive Officer of OphthaliX Inc.

          Hebrew version

          English version

  November 13, 2012
Can-Fite BioPharma to Develop a Drug for the Treatment of Sexual Dysfunction

          Hebrew version

          English version 

  November 4, 2012
Can-Fite BioPharma Receives Quotation Clearance for Its Level 1 ADRs

          Hebrew version

          English version

  October 9, 2012
Interim Analysis Supports Continuation of Can-Fite’s Phase 2/3 Psoriasis Clinical Study with CF101

          Hebrew version

          English version

  October 4, 2012
Can-Fite BioPharma Begins Trading in U.S. through Launch of ADRs

          Hebrew version

          English version

  September 9, 2012
Can-Fite BioPharma is progressing towards trading in the US via ADRs

          Hebrew version

          English version

  July 3, 2012
Can-Fite BioPharma announces its intention to register ADRs in the US

           Hebrew version

           English version

  May 21, 2012
Can-Fite BioPharma: the Israeli Government`s Office of the Chief Scientist Approved a Research Grant to support the development of CF102 for Primary Liver Cancer
           Hebrew version

           English version
  April 23, 2012
Can-Fite BioPharma announces the completion of enrolment of the first 100 patients for it’s Psoriasis Phase II/III clinical study with CF101

           Hebrew version

           English version

  April 10, 2012
Can-Fite: OphthaliX Successfully Completed Preclinical Studies Showing the Efficacy of CF101 for the Treatment of Anterior Uveitis
           Hebrew version

           English version
  February 22, 2012
FDA grants Orphan Drug Status for CF102 for the Treatment of Hepatocellular Carcinoma

           Hebrew version

           English version

  February 22, 2012
OphthaliX announces issuance of Chinese Patent for the treatment of Dry Eye Disorders

           Hebrew version

           English version

  February 6, 2012
OphthaliX announces the appointment of Prof. Roger Kornberg as a Director.

 

           Hebrew version

           English version
  January 3, 2012
Can-Fite BioPharma announces successful results of its Phase I/II Liver Cancer study with its CF102 Drug; the Study achieved the primary and secondary endpoints.

           Hebrew version

           English version

2011

 

  December 21, 2011
OphthaliX Announces the Commencement of Patient Enrollment for the Phase 3 Dry Eye Syndrome Study.
           Hebrew version

           English version
  November 22, 2011
Can-Fite is spinning off its ophthalmic indications to a US based public company in a $50 million valuation.

           Hebrew version

           English version

  August 1, 2011
Can-Fite Announces the Initiation of Patient Enrolment for the Phase 2/3 Psoriasis Study with its Lead Drug CF101.

           Hebrew version

           English version

  June 5, 2011
OCan-Fite Signed an Agreement to Spin off its Ophthalmology Activities to a US Based Public Company.

 

           Hebrew version

           English version
  May 11, 2011
Can-Fite announces a promising interim analysis data of its Phase I/II Liver Cancer study with the CF102 Drug.

           Hebrew version

           English version

2010

 

  September 6, 2010
Can-Fite announces the initiation of phase 3 in Dry Eye Syndrome.
           Hebrew version

           English version
  July 25, 2010
Can-Fite drug candidate CF102 significantly decreased viral load of HCV in 3 Patients with Liver Cancer.

           Hebrew version

           English version

  May 30, 2010
Can-Fite’s drug CF102 significantly decreased viral load of HCV in a Patient with Liver Cancer.

           Hebrew version

           English version

  May 23, 2010
Can Fite BioPharma Receives Israeli MoH Approval to Conduct a Phase II Clinical Trial Evaluating the Efficacy of CF101 in Patients with Glaucoma.

 

           Hebrew version

           English version
  March 31, 2010
Can Fite steps forward to the 3rd and last stage of its Phase I/II Liver Cancer study with the CF102 Drug.

           Hebrew version

           English version

  Januay 19, 2010
Morningside and Can Fite BioPharma to Establish a Joint Venture to Develop and Commercialize Can-Fite’s CF102 Drug for the Treatment of Liver Diseases.

           Hebrew version

           English version

2009

 
  December 13, 2009
Can-Fite BioPharma to Initiate Phase II Clinical Trial with CF101 for the Treatment of Glaucoma.
           Hebrew version

           English version
  November 24, 2009
Following the successful completion of two phase II clinical trials, Can Fite BioPharma retains Plexus Ventures to Partner their Phase II Lead Compound, Developed for Psoriasis and Other Indications.

           Hebrew version

           English version

  September 29, 2009
Can-Fite Initiates Preparatory Work for Psoriasis Phase III Trial with CF101.

           Hebrew version

           English version

  September 7, 2009
Can-Fite Announces Positive Results from its Psoriasis Phase II Trial with CF101.

 

           Hebrew version

           English version
  July 28, 2009
Can-Fite BioPharma Expands its Pipeline by Licensing Allosteric Modulators from Leiden University and the NIH.

           Hebrew version

           English version

  July 14, 2009
Can-Fite BioPharma to Initiate Phase I/II Clinical Trial with CF102 for the Treatment of Hepatitis C Virus. About 180 milion people of the world’s population are infected with HCV; The HCV market cap is currently estimated to be US$ 3 billion.

           Hebrew version

           English version

  May 31, 2009
Can-Fite Completed Patient Enrollment for the Phase II Trial in Psoriasis with CF101. The patients were treated with CF101 as a stand alone similarly to the patients in the successful Dry Eye study. The Psoriasis market cap is currently estimated to be US$ 3.5 billion.

           Hebrew version

           English version

  May 17, 2009
Can-Fite Announces Positive Results from its Phase II Trial Treating Keratoconjunctivitis Sicca (Dry Eye Syndrome) with CF101. Dry Eye affects more than 20 million people in the US alone.

 

           Hebrew version

           English version
  April 30, 2009
A Phase IIb Study Testing the Combination of Methotrexate and CF101 in Rheumatoid Arthritis Patients Failed to Achieve Primary Efficacy Endpoint. Can-Fite Continues to Develop CF101 as a Stand-alone Therapy for Other Clinical Indications.

           Hebrew version

           English version

  April 16, 2009
Can-Fite BioPharma to Initiate Phase I/II Clinical Trial with CF102 for the Treatment of Liver Cancer. Liver cancer is one of the five most common types of cancer globally, accounting for about 450,000 new diagnoses each year. Can-Fite expects to release within weeks the results of a phase IIB trial with CF101 for the treatment of rheumatoid arthritis and Phase IIa trial for the treatment of Dry Eye Syndrome.

           Hebrew version

           English version

  January 28, 2009
Can-Fite Completed Patient Enrollment for the Phase II Trial in Dry Eye Syndrome with CF101. Company estimates to release data on Q2 2009. The Dry Eye Syndrome market cap is currently estimated to be US$ 1 billion.

           Hebrew version

           English version

2008

 
  December 29, 2008
Can-Fite Completed Patient Enrollment for the Confirmatory Phase IIb Trial in Rheumatoid Arthritis Patients with CF101. Company estimates to release data on Q2 2009. The arthritis market cap is currently estimated to be US$ 11 billion.
           Hebrew version

           English version
  December 22, 2008
Out License of Rights for CF101 in Korea to Kwang Dong Pharmaceutical Co. Ltd. Can-Fite Expects to Receive US$ 1.5 Million from Licensing Fees and Milestone Payments in addition to Substantial Royalties. Additionally, Kwang Dong will also purchase equity in Can-Fite in an amount representing approximately 1% of Can-Fite’s outstanding share capital at a premium of 50% above market priceS.

           Hebrew version

           English version

  September 9, 2008
Can-Fite signs MOU with the Korean company Kwang Dong Pharmaceutical for licensing CF101 rights for Korea.

           Hebrew version

           English version

  August 17, 2008
Can-Fite BioPharma: Seikagaku Corporation, the Exclusive Licensee of CF101 in Japan, is to Commence Phase I Clinical Trial in Japan with CF101 for the Treatment of Rheumatoid Arthritis. Can-Fite will receive USD 1 M upon clinical study initiation.

 

           Hebrew version

           English version
  May 4, 2008
Can-Fite Successfully Completed Phase I Clinical Trial with its 2nd Drug CF102. Prepares for next phase of clinical trials in liver diseases.

           Hebrew version

           English version

  April 1, 2008
Can-Fite: First Patient was enrolled to the Phase IIb Rheumatoid Arthritis Trial. The study will include 230 RA patients at 30 medical sites in Europe and Israel.Rheumatoid Arthritis market is currently estimated at about $11 billion.

           Hebrew version

           English version

  February 17, 2008
Can-Fite Initiated Phase I Clinical Trial with CF102. First Cohort was Successfully Completed. CF102 is indicated for the treatment of liver diseases.

           Hebrew version

           English version

  January 16, 2008
Can-Fite and NIH Signed a Continuation of M-CRADA to Further Investigate CF101 for the Treatment of Uveitis. The agreement was signed based on positive data generated at leading lab at the National Eye Institute (NEI) at the NIH. A successful collaboration will prompt Can-Fite to the conductance of a Phase II clinical trial to test the efficacy of CF101 in the treatment of Uveitis. Uveitis is an inflammatory disease that involves the internal parts of the eye; it affects about 1 million people worldwide and its current market is estimated at about half a billion dollars.

 

           Hebrew version

           English version
  January 7, 2008
Can-Fite Receives FDA Approval to Conduct Phase I Study with CF102. IND application submitted by Can-Fite last month was approved; phase I study will be initiated in the US in Q1 2008. The Company also received $0.5 million minimal royalty payment on CF101 from Seikagaku Corporation (SKK).

           Hebrew version

           English version

2007

 
  December 30, 2007
Can-Fite to Collaborate with Leading Academic Institutes in the Development of CF102. Under this collaboration the effect of CF102 on HCV replication in hepatocytes and molecular mechanisms involved with the antiviral activity of CF102 will be explored. Agreements were signed with world leading laboratories in the field of virology at the Israel`s Rabin Medical Center and Temple University in Philadelphia.
           Hebrew version

           English version
  December 2, 2007
Can-Fite: IND submission for Phase I Clinical Trials with its Drug for Liver Diseases CF102. Can-Fite develops CF102 for the treatment of liver cancer, hepatitis virus infections and other liver conditions that represent a current market of about USD 4 billion. Can-Fite estimates that this Phase I study will be initiated in early 2008, subject to FDA approval.

           Hebrew version

           English version

  November 6, 2007
Can-Fite: CF101 may be Effective for the Treatment of Crohn`s Disease. Market size in the US alone, with about 500,000 Crohn`s patients is estimated at approximately USD 5 billion. Can-Fite will present these results at the annual meeting of the American College of Rheumatology (ACR), held this week in Boston.

           Hebrew version

           English version

  October 23, 2007
Can-Fite to Conduct a Confirmatory Phase IIb Trial in Early 2008 as Part of Ongoing Development of CF101 for the Treatment of Rheumatoid Arthritis. Can-Fite`s Clinical Advisory Board has recommended this advanced trial as further evidence for the efficacy observed in a previous trial; this will give green light to the final phase of development.

 

           Hebrew version

           English version
  October 21, 2007
Can-Fite: CF102 Drug is Effective in Promoting Liver Tissue Regeneration; Clinical Trials with CF102 in the Treatment of Liver Cancer are Due to Commence in Early 2008. Can-Fite filed a patent on the use of the drug to promote liver tissue regeneration; this is in addition to the original indication in the treatment of liver cancer and viral hepatitis.

           Hebrew version

           English version

  October 16, 2007
Can-Fite Achieved Additional Milestone Payment within the Framework of its Agreement with Seikagaku Corporation (SKK): To Receive $500,000. The total sum paid by SKK to Can-Fite to date amounts to $5 million. Can-Fite and SKK are jointly pursuing several non-clinical studies in the US aimed at supporting CF101 drug development.

           Hebrew version

           English version

  September 24, 2007
Can-Fite Develops a Blood Test to Predict Patients’ Response to the Company Drugs. The test measures blood levels of the A3 adenosine receptor, the target attacked by Can-Fite`s drugs; the test will predict patient’s response to treatment. The Company has applied for a patent to protect this technology.

           Hebrew version

           English version

  August 19, 2007
Can-Fite Successfully Completes Preclinical Trials with its second Drug Candidate CF102. Soon to submit to the FDA an application for a phase I clinical trial.

 

           Hebrew version

           English version
  July 24, 2007
Can-Fite: Pre-clinical Studies demonstrate that the Excipients used in the Placebo and CF101 Drug Enhanced the Anti-inflammatory Effect of Methotrexate (MTX).

           Hebrew version

           English version

  July 15, 2007
Can-Fite Reports Results of a Phase IIb Clinical Study in Rheumatoid Arthritis with CF101, an A3 Adenosine Receptor Agonist. The Results Support Further Clinical Development of CF101.

           Hebrew version

           English version

  June 13, 2007
CCan-Fite Proceeds with Development of Third Drug; Progress in Development of CF502 will be Presented at the Annual European Congress of Rheumatology.

           Hebrew version

           English version

  June 3, 2007
Can-Fite Successfully Completes Long-Term Toxicology Studies with CF101 in full GLP compliance with US FDA.

           Hebrew version

           English version

  May 16, 2007
Can-Fite to Commence Phase II Clinical Trials to Investigate the Efficacy of CF101 in the Treatment of Psoriasis. The market for psoriasis therapies is estimated at about USD 3 billion. The Company has also completed the clinical portion of a phase IIb clinical trial for the treatment of rheumatoid arthritis, the results of which are expected to be released this summer.

           Hebrew version

           English version

  March 7, 2007
Can-Fite Completes NIS 40 Million Private Placement of Shares and Options Within One Day. Due to over-subscription during the rapid issuance, the Company resolved to increase the capital-raising round by 19% more than originally planned .

           Hebrew version

           English version

  February 18, 2007
Breakthrough for Can-Fite: CF102 Found to be Active against Hepatitis B Virus in Pre-Clinical Studies. Company signs collaboration agreement with leading laboratory at Philadelphia`s Temple University to test the drug`s antiviral activity.

           Hebrew version

           English version

  January 14, 2007
Can-Fite progresses through clinical trials: completed enrolment of 250 patients in phase IIb rheumatoid arthritis (RA) trial. Can-Fite will receive a consideration of US$ 500,000 from Japanese Seikagaku Corporation for achieving another milestone under the joint agreement, and a further US$ 500,000 in royalties.

           Hebrew version

           English version

2006

 
  December 19, 2006
Can-Fite granted US patent on CF101 for Rheumatoid Arthritis (RA). The patent confers exclusive right to CF101 in the treatment of RA until 2023 .
           Hebrew version

           English version
  November 12, 2006
Can-Fite presents results showing a correlation between high expression of the receptor target for its drug CF101 and rheumatoid arthritis patients’ response to the drug.

           Hebrew version

           English version

  October 23, 2006
Can-Fite progresses through clinical trials: completed enrolment of half the patients required for phase IIb RA trial and is scheduled to receive next payment from the Japanese Seikagaku Corporation.

           Hebrew version

           English version

  October 8, 2006
Can-Fite to Develop CF102 for the Treatment of Liver Cancer. Canfite is currently conducting all the IND-enabling work that will support the initiation of Phase I clinical trials in Liver Cancer patients towards the end of 2007 .

 

           Hebrew version

           English version
  September 25, 2006
Can-Fite Expects to Receive Up to US$ 19.5 Million from a Japanese Company and Collect Substantial Royalties from the Grants of Licensing Rights to Develop and Market CF101 in Japan .

           Hebrew version

           English version

  September 10, 2006
Can-Fite to Develop CF101 for Psoriasis, Among Other Indications.
The company will commence preparations for phase II clinical trial in psoriasis.

           Hebrew version

           English version

  September 05, 2006
Can-Fite BioPharma Received Israeli MoH Approval to Conduct a Clinical Trial Evaluating the Efficacy of CF101 in Patients with Dry Eye Syndrome.

           Hebrew version

           English version

  July 18, 2006
Can-Fite Fite Initiated Phase IIb Clinical Trials in Rheumatoid Arthritis Patients; has achieved milestones enabling it to convert issued debentures. The Company has received the final report summarizing the results of the Phase IIa clinical trial in Rheumatoid Arthritis patients, demostrating a decrease in disease parameters.

 

           Hebrew version

           English version
 

June 25, 2006
Can-Fite on its way to Initiate Clinical Trials with Second Drug – CF102. Company initiated non-clinical developmenty of the drug.

           Hebrew version

           English version

  June 14, 2006
The drug CF101 is not metabolized in the liver and can be used as potential therapy for liver related conditions.

           Hebrew version

           English version

  May 16, 2006
214 Times Oversubscribed. Can-Fite Biopharma Concluded a NIS 30 Million Fund-raising for Funding Clinical Studies and Ongoing R&D.

           Hebrew version

           English version

  April 3, 2006
Can-Fite Signs an MOU for Out-licensing Rights of CF101 for Inflammatory Indications in Japan .

           Hebrew version

           English version

  April 3, 2006
Can-Fite to Initiate Clinical Studies to Test Efficacy of CF101 in Treating Dry Eyes Syndrome.

           Hebrew version

           English version

  March 13, 2006
Can-Fite Biopharma Files Two New Patent Applications Relating to Very Important Therapeutic Indications.

           Hebrew version

           English version

  February 6, 2006
Can-Fite Biopharma Appointed Dr. Ilan Cohn as Vice Chairman of the Board .

           Hebrew version

           English version

  January 30, 2006
New Clinical Data on the Effect of CF101 in Improving Dry Eye Symptoms.

           Hebrew version

           English version

  January 24, 2006
Can-Fite BioPharma Signed a Cooperative Research and Development Agreement (CRADA) with the US National Institute of Health (NIH).

           Hebrew version

           English version

  January 22, 2006
Can-Fite Submitted its Protocol for a Phase IIb Clinical Study of CF101 in Rheumatoid Arthritis Patients to the US Food and Drug Administration (FDA). The Multinational Phase IIb Clinical Study Scheduled to Begin in Q2 of 2006.

           Hebrew version

           English version

2005

 
  December 19, 2005
Can-Fitee Announces Successful Completion of a Public Offering
           Hebrew version

           English version
  December 6, 2005
The Shareholders of Can-Fite BioPharma will be Requested to Approve the Appointment of Dr. Itzhak Krinsky, Vice President in Teva Pharmaceutical Industries and Prof. Yechezkel Barenholz from the Hebrew University as External Directors in the Company.

           Hebrew version

           English version

  November 6, 2005
Data Demonstrating Positive Activity of CF101 in Rheumatoid Arthritis Patients will be Presented in the Forthcoming Annual Scientific Meeting of the American College of Rheumatology.

           Hebrew version

           English version

  October 10, 2005
Michael Weiss, the Chairman and CEO of Keryx Biopharmaceuticals, Joins as an Observer of the Board of Directors of Can-Fite.

 

           Hebrew version

           English version
  September 26, 2005
Israeli Biopharmaceutical Company "Can-Fite BioPharma" to raise NIS 45 million on the Tel-Aviv Stock Exchange. Michael Weiss and Alex Rabinovitch granted options for their contribution in raising investment interests.

           Hebrew version

           English version